Addex Therapeutics Ltd (ADXN) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Addex Therapeutics Ltd (ADXN) closed at USD 2.65 on 2026-10-14, a change of -72 % over the past year, with a market capitalization of USD 5.29M.
Addex Therapeutics Ltd recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 2.65 |
| 2026-10-13 | 3.01 |
| 2026-10-12 | 3.04 |
| 2026-10-09 | 3.22 |
| 2026-10-08 | 3.18 |
| 2026-10-07 | 3.13 |
| 2026-10-06 | 3.18 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Addex Therapeutics Ltd key figures
- Previous close
- USD 2.65 (2026-10-14)
- 1-year change
- -72 %
- Market cap
- USD 5.29M
- Enterprise value
- USD 2.52M
- P/E ratio (trailing)
- -0.40
- P/E ratio (forward)
- -60.40
- EPS (trailing)
- -7.56
- EPS (forward)
- -0.05
- PEG ratio
- n/a
- Price to book
- 1.40
- Revenue growth
- -72.7 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.05
- Employees
- 3
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Addex Therapeutics Ltd and compare it with other stocks.
Analyze ADXNAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Addex Therapeutics Ltd shares.